Earlier is better for HPV vaccination. A cluster randomized trial found that children were more than twice as likely to start and complete the HPV vaccine series when clinics began recommending it at ages 9–10 instead of 11–12. The shift also moved completion a full year earlier — a meaningful win for cancer prevention at the population level.
Earlier is better for HPV vaccination
A large cluster randomized controlled trial presented at IDWeek found that simply shifting the recommended age for HPV vaccination from 11–12 to 9–10 years old dramatically improved both initiation and completion rates. The 5-year study, conducted across 31 pediatric clinics in Colorado and California, enrolled more than 62,000 children and adolescents — and the results were striking.
Children at clinics recommending earlier vaccination completed the series a full year sooner (median age 12.2 vs. 13.3 years) and were more than twice as likely to both start and finish the series. Researchers also noted no negative effects on clinic visits or uptake of other vaccines, and parental pushback was no greater than usual.
By the Numbers
Why it matters: The HPV vaccine protects against 6 cancers and works best before exposure. With uptake still far below national targets, recommending the vaccine at ages 9–10 offers a practical, evidence-backed strategy to close the gap — without requiring new resources or policy overhauls.
